SCHEMBL1803530

SCHEMBL1803530

[2H]C(C)(C)I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552679 0.75
SCHEMBL434703 0.75
SCHEMBL1333515 0.75
SCHEMBL508447 0.75
SCHEMBL715205 0.72
SCHEMBL40927 0.72
Isobutane SCHEMBL30260038 0.72
SCHEMBL5555 0.72
Iodoform SCHEMBL2755155 0.72
SCHEMBL2755344 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3296295-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES American Life Science Pharmaceuticals, Inc. (US) 2018-03-21 EP disclosed
EP-2921486-B1 Compositions and methods for treating beta-amyloid related diseases AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
US-20170008918-A1 NOVEL CYP-EICOSANOID DERIVATIVES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-01-12 US disclosed
EP-2921486-A1 Compositions and methods for treating beta-amyloid related diseases American Life Science Pharmaceuticals, Inc. (US) 2015-09-23 EP disclosed
EP-2462131-B1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2014-10-15 EP disclosed
US-20110105603-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) 2011-05-05 US disclosed
US-20090062561-A1 DEUTERIUM-ENRICHED LATANOPROST PROTIA, LLC (US) 2009-03-05 US disclosed